Tumor progression in lymphoma
Recent publications
Zhao WL, Liu YY, Zhang QL, Wang L, Leboeuf C, Zhang YW, Ma J, Garcia JF, Song YP, Li JM, Shen ZX, Chen Z, Janin A, Chen SJ. PRDM1/BLIMP-1 is involved in chemoresistance of T-cell lymphoma and downregulated by the proteasome inhibitor. Blood 2008, 111:3867-3871 2008 Dec;14(12):1333-42.
Liu YY, Leboeuf C, Shi JY, Li JM, Wang L, Shen Y, Garcia JF, Shen ZX, Chen Z, Janin A, Chen SJ, Zhao WL. Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma. Blood 2007, 110: 339-344
Zhao WL, Wang L, Liu YH, Yan JS, Leboeuf C, Liu YY, Wu WL, Janin A, Chen Z, Chen SJ. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis. Experimental Hematology 2007, 35: 1801-1811
Liu YH, Leboeuf C, Jin XL, Xiao JC, Janin A, Chen SJ, Zhao WL: [BCL-XL expression and mutation in non-Hodgkin's lymphoma], Zhongguo Shi Yan Xue Ye Xue Za Zhi 2006, 14:903-907
Zhao WL, Daneshpouy ME, Mounier N, Briere J, Leboeuf C, Plassa LF, Turpin E, Cayuela JM, Ameisen JC, Gisselbrecht C, Janin A: Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma, Blood 2004, 103:695-697
Zhao WL, Mourah S, Mounier N, Leboeuf C, Daneshpouy ME, Legres L, Meignin V, Oksenhendler E, Maignin CL, Calvo F, Briere J, Gisselbrecht C, Janin A: Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression, Lab Invest 2004, 84:1512-1519
